Oncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial

Stock Information for Oncocyte Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Oncocyte Corporation

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles
Oncocyte Signs Leading Transplant Centers in US and Germany
Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
PRISM MarketView Features Oncocyte CFO Andrea S. James on Her Career and Leadership in Molecular Diagnostics Technology
Sidoti Events, LLC's Virtual August Micro-Cap Conference
Oncocyte's VitaGraft(TM) Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study
Oncocyte Announces Successful GraftAssure(TM) Beta Launch and Q2 2024 Results
Oncocyte Announces August Investor Conferences Participation

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.